The FDA has given pharma giant Pfizer ($PFE) a fast-track review of its drug tafamidis meglumine for treating the rare disease known as transthyretin familial amyloid polyneuropathy, meaning the agency is set to decide on the drugmaker's application for approval by June, The Wall Street Journal reported. The fast-track designation boosts Pfizer's move into the rare disease drug segment, which has attracted lots of attention from the company and its Big Pharma counterparts because of its blockbuster prospects. Pfizer picked up tafamidis meglumine via its FoldRx buyout in 2010. Report